Suppr超能文献

药物经济学指南:印度当下的需求。

Pharmacoeconomics guidelines: The need of hour for India.

作者信息

Oberoi Sukhvinder Singh, Oberoi Avneet

机构信息

Department of Public Health Dentistry, Sudha College of Dental Sciences and Research, Faridabad, Haryana, India.

Department of Public Health Dentistry, Oberoi Dental Clinic and Orthodontic Centre, Tagore Garden, New Delhi, India.

出版信息

Int J Pharm Investig. 2014 Jul;4(3):109-11. doi: 10.4103/2230-973X.138338.

Abstract

Although the government pays for approximately 20% of drugs used in India, private out-of-pocket expenditure in India on health-care is one of the highest in the world. Preparing pharmacoeconomics guidelines will be an important step in order to establish Health Technology Assessment (HTA) in India. Areas in which HTA could be applied in the Indian context include, drug pricing, development of clinical practice guidelines and prioritizing interventions that represent the greatest value within a limited budget. All this calls for action, both by government and civil-society organizations, to make access to essential medicines a priority.

摘要

尽管印度政府支付了约20%的药品费用,但印度民众在医疗保健方面的自付费用却是世界上最高的之一。制定药物经济学指南将是在印度建立卫生技术评估(HTA)的重要一步。在印度背景下,HTA可应用的领域包括药品定价、临床实践指南的制定以及在有限预算内对最具价值的干预措施进行优先排序。所有这些都需要政府和民间社会组织采取行动,将基本药物的可及性作为优先事项。

相似文献

1
Pharmacoeconomics guidelines: The need of hour for India.
Int J Pharm Investig. 2014 Jul;4(3):109-11. doi: 10.4103/2230-973X.138338.
2
Health technology assessment and its role in the future development of the Indian healthcare sector.
Perspect Clin Res. 2012 Apr;3(2):66-72. doi: 10.4103/2229-3485.96449.
3
Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Value Health. 2009 Nov-Dec;12 Suppl 3:S18-25. doi: 10.1111/j.1524-4733.2009.00622.x.
4
Value added medicines: what value repurposed medicines might bring to society?
J Mark Access Health Policy. 2016 Dec 23;5(1):1264717. doi: 10.1080/20016689.2017.1264717. eCollection 2017.
6
Rational use of medicines - Indian perspective!
Int J Risk Saf Med. 2015;27 Suppl 1:S47-8. doi: 10.3233/JRS-150684.
7
Capacity Building for Health Technology Assessment in Jordan: Institutionalization and Its Use in Pricing and Reimbursement Decisions.
Value Health Reg Issues. 2022 Nov;32:47-53. doi: 10.1016/j.vhri.2022.07.006. Epub 2022 Sep 5.
8
Can Health Technology Assessment (HTA) provide a solution to tackle the increasing health-care expenditure in India?
Indian J Public Health. 2016 Apr-Jun;60(2):138-41. doi: 10.4103/0019-557X.184570.
9
Budgeting for a billion: applying health technology assessment (HTA) for universal health coverage in India.
Health Res Policy Syst. 2018 Nov 29;16(1):115. doi: 10.1186/s12961-018-0378-x.
10
The role of pharmacoeconomics in current Indian healthcare system.
J Res Pharm Pract. 2013 Jan;2(1):3-9. doi: 10.4103/2279-042X.114081.

引用本文的文献

1
Pharmacoeconomic Aspects of Diabetes Mellitus: Outcomes and Analysis of Health Benefits Approach.
Curr Diabetes Rev. 2024;20(8):12-22. doi: 10.2174/0115733998246567230924134603.
2
An Assessment of the Availability of Essential Medicines in Gadag Taluk, Karnataka: A Study of Primary Health Centers.
Cureus. 2023 May 22;15(5):e39341. doi: 10.7759/cureus.39341. eCollection 2023 May.
3
Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries.
Int J Environ Res Public Health. 2022 Jun 27;19(13):7862. doi: 10.3390/ijerph19137862.
4
Availability of medicines in public sector health facilities of two North Indian States.
BMC Pharmacol Toxicol. 2015 Dec 23;16:43. doi: 10.1186/s40360-015-0043-8.

本文引用的文献

1
Health technology assessment and its role in the future development of the Indian healthcare sector.
Perspect Clin Res. 2012 Apr;3(2):66-72. doi: 10.4103/2229-3485.96449.
3
Access to essential medicines in national constitutions.
Bull World Health Organ. 2010 Nov 1;88(11):800. doi: 10.2471/BLT.10.078733.
5
Helping poorer countries make locally informed health decisions.
BMJ. 2010 Jul 16;341:c3651. doi: 10.1136/bmj.c3651.
6
Evidence-based decision on medical technologies in Asia Pacific: experiences from India, Malaysia, Philippines, and Pakistan.
Value Health. 2009 Nov-Dec;12 Suppl 3:S18-25. doi: 10.1111/j.1524-4733.2009.00622.x.
7
Growing application of pharmacoeconomics and outcomes research in health-care decision-making in the Asia-Pacific region.
Value Health. 2009 Nov-Dec;12 Suppl 3:S1-2. doi: 10.1111/j.1524-4733.2009.00618.x.
8
Health systems financing and the path to universal coverage.
Bull World Health Organ. 2010 Jun;88(6):402. doi: 10.2471/BLT.10.078741.
9
Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases.
Bull World Health Organ. 2009 Jul;87(7):520-8. doi: 10.2471/blt.08.058925.
10
Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis.
Lancet. 2009 Jan 17;373(9659):240-9. doi: 10.1016/S0140-6736(08)61762-6. Epub 2008 Nov 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验